References

1. Bostrom PJ, Bjartell AS, Catto JW, et al. Genomic Predictors of Outcome in Prostate Cancer. *European Urology.* Dec 2015;68(6):1033-1044.

2. Marrone M, Potosky AL, Penson D, Freedman AN. A 22 Gene-expression Assay, Decipher(R) (GenomeDx Biosciences) to Predict Five-year Risk of Metastatic Prostate Cancer in Men Treated with Radical Prostatectomy. *PLoS Currents.* Nov 17 2015;7.

3. Moschini M, Spahn M, Mattei A, Cheville J, Karnes RJ. Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics. *BMC Medicine.* Apr 04 2016;14:67.

4. AHRQ. Gene expression profiling for predicting outcomes in patients with stage II colon cancer. 2012.

5. Decipher website. Available at: deciphertest.com/.

6. OncotypeDX website. Available: www.oncotypedx.com/.

7. Prolaris website. Available at: prolaris.com/.

8. ProMark website. Available at: metamarkgenetics.com/healthcare-professionals/our-lab-services/promark.

9. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. V1.2017. Available at: www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf.

10. Tomlins SA, Alshalalfa M, Davicioni E, et al. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. *European Urology.* Oct 2015;68(4):555-567.

11. Knudsen BS, Kim HL, Erho N, et al. Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens. *The Journal of Molecular Diagnostics.* May 2016;18(3):395-406.